Gyre Therapeutics (GYRE) Cash from Operations (2010 - 2026)
Gyre Therapeutics (GYRE) reported Cash from Operations of 3200000.0 for Q1 2026, up 2580.62% year-over-year from 119375.36 in Q1 2025, and up 157.14% quarter-over-quarter from 5600000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Cash from Operations (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Cash from Operations data on file, last reported at 3200000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 3200000.0, up 2580.62% year-over-year; the trailing twelve-month figure through Mar 2026 was 4329000.0 (up 165.06% YoY), and the FY2025 annual result was 1000000.0, up 127.46% from the prior year.
- Cash from Operations advanced to 3200000.0 in Q1 2026 per GYRE's latest filing, from 5600000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 42298000.0 in Q4 2022 and troughed at 12294000.0 in Q2 2022.
- A 5-year average of 2184000.0 and a median of 2129000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2026: Cash from Operations tumbled 221.18% in 2024, then surged 2580.62% in 2026.
- A 5-year view of Cash from Operations shows it stood at 42298000.0 in 2022, then sank by 92.06% to 3360000.0 in 2023, then slumped by 182.08% to 2758000.0 in 2024, then plunged by 103.05% to 5600000.0 in 2025, then jumped by 157.14% to 3200000.0 in 2026.
- Business Quant data shows GYRE's Cash from Operations at 3200000.0 in Q1 2026, 5600000.0 in Q4 2025, and 4600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.20 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Dec 31, 2024 | -2.76 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | 3.36 Mn |
| Dec 31, 2023 | 3.36 Mn |